Planning Grant for Parasitic Ulcer Treatment Trial
Planning Grant for Parasitic Ulcer Treatment Trial
批准号:
8464121
负责人:
Jeremy David Keenan
金额:
$21.98万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2014-10-31
关键词:
AcanthamoebaAcanthamoeba KeratitisAddressAdherenceAdrenal Cortex HormonesAdvocateBiguanidesCaliforniaCase SeriesCharacteristicsChicagoChlorhexidineClinicalClinical ResearchClinical TrialsCollaborationsCombined Modality TherapyConduct Clinical TrialsConfocal MicroscopyContact LensesCorneaCystDiagnosisDiagnosticDiagnostic testsDisadvantagedDiseaseDisease OutbreaksEffectivenessEnrollmentEvidence based treatmentEyeGoalsGoldGrantGrowthHospitalsIllinoisIndiaInfectionInflammationLeadLocal Anti-Infective AgentsMethodsOphthalmologistOralOutcomePainPatientsPharmaceutical PreparationsPhasePhysiciansPlacebosPolymerase Chain ReactionProtocols documentationRandomizedRandomized Clinical TrialsRandomized Controlled TrialsRecruitment ActivityRecurrenceRegimenRelative (related person)ResearchRiskRoleSan FranciscoSensitivity and SpecificitySpecialistStudy SubjectTestingTimeTopical CorticosteroidsToxic effectTreatment ProtocolsUlcerUnited StatesUniversitiesVisionVisitVisual AcuityVisual impairmentVoriconazoleWorkantimicrobial drugcare systemsevidence baseimprovedmicrobialocular painpathogenpolyhexamethylene biguanideprospectivetreatment trialtrial comparing
中文摘要
描述(由申请人提供):本研究的目的是计划一项临床试验,以确定诊断和治疗棘阿米巴角膜炎的更好方法。棘阿米巴角膜炎是一种致盲性角膜感染,在美国是一种越来越常见的导致视力损害的原因。棘阿米巴角膜炎很难诊断,因为临床症状是非特异性的,即使存在感染,培养也可能呈阴性。理想的治疗方案尚不清楚。大多数角膜专家使用多种局部和口服药物治疗。然而,多种药物可能并不比单一药物更有效,并且多种药物的使用具有角膜毒性和较差的依从性的缺点。局部使用皮质类固醇治疗棘阿米巴角膜炎是有争议的。一些角膜专家反对使用皮质类固醇,因为它们已被证明会促进棘阿米巴的增殖。其他人使用皮质类固醇作为辅助治疗来减轻炎症和疼痛。本研究旨在完善棘阿米巴角膜炎诊断和治疗的证据基础,具体目的如下:1)确定几种棘阿米巴角膜炎诊断检测的敏感性和特异性,包括临床检查;
英文摘要
DESCRIPTION (provided by applicant): The objective of this study is to plan for a clinical trial to determine better ways to diagnose and treat acanthamoeba keratitis. Acanthamoeba keratitis is a blinding corneal infection that is an increasingly common cause of visual impairment in the United States. Acanthamoeba keratitis can be difficult to diagnose, since clinical signs are nonspecific, and cultures can be negative even if infection is present. The ideal treatment regimen is not clear. Most corneal specialists treat with multiple topical and oral agents. However, multiple agents may not be more effective than a single agent, and the use of multiple agents has the disadvantages of corneal toxicity and worse adherence. The use of topical corticosteroids for acanthamoeba keratitis is controversial. Some cornea specialists oppose the use of corticosteroids, since they have been shown to promote acanthamoeba proliferation. Others have used corticosteroids as an adjunctive therapy to reduce inflammation and pain. In this study, we expect to improve the evidence base for the diagnosis and management of acanthamoeba keratitis, through the following specific aims: 1) To determine the sensitivity and specificity of several diagnostic tests for acanthamoeba keratitis, including clinical examination,
culture, smear, PCR, and confocal microscopy. 2) To determine whether patients randomized to single agent therapy for acanthamoeba keratitis with topical chlorhexidine have similar microbial cure times compared to those randomized to multiple agent therapy with topical chlorhexidine and propamidine plus oral voriconazole 3) To determine whether patients being treated for acanthamoeba keratitis who are randomized to topical corticosteroids will have better vision compared to those randomized to a placebo. Large clinical studies for acanthamoeba have traditionally proven difficult, because while the risk of acanthamoeba keratitis is significan for contact lens wearers, relatively few cases present at any one center. We address this by establishing a collaboration between 3 centers: the University of California, San Francisco, the University of Illinois at Chicago, and the Aravind Eye Hospitals in India. As a result, the proposed study would make up the largest prospective randomized study on acanthamoeba keratitis ever performed, and only the second randomized clinical trial. During the course of the planning period, we propose to finalize the study protocol and statistical analysis plan, and to start recruiting study subjects in order to assess enrollment potential.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Antiamoebic Susceptibility in Acanthamoeba Keratitis: Comparison of Isolates From South India and Northern California.
棘阿米巴角膜炎的抗阿米巴药敏感性:南印度和北加州分离株的比较。
DOI:
10.1097/ico.0000000000003060
发表时间:
2023
期刊:
Cornea
影响因子:
2.8
作者:
[Richardson,QuintinR, Prajna,Lalitha, Elakkiya,Shanmugam, Kamal,FathimaSulthana, Talbott,Maya, Prajna,NamperumalsamyVenkatesh, Rajaraman,Revathi, Cevallos,Vicky, Seitzman,GeramiD, Lietman,ThomasM, Keenan,JeremyD]
通讯作者:
Keenan,JeremyD
Parasitic Ulcer Treatment Trial
-
批准号:10626567
-
项目类别:
-
资助金额:$156.21万
-
财政年份:2023
-
负责人:Jeremy David Keenan
-
依托单位:
Integrating smartphone photography for trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring
-
批准号:10908756
-
项目类别:
-
资助金额:$29.69万
-
财政年份:2023
-
负责人:Jeremy David Keenan
-
依托单位:
Integrating smartphone photography for trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring
-
批准号:10487468
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2021
-
负责人:Jeremy David Keenan
-
依托单位:
Integrating smartphone photography for trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring
-
批准号:10268577
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2021
-
负责人:Jeremy David Keenan
-
依托单位:
Village-Integrated Eye Worker trial II (VIEW II)
-
批准号:10441468
-
项目类别:
-
资助金额:$67.83万
-
财政年份:2018
-
负责人:Jeremy David Keenan
-
依托单位:
Village-Integrated Eye Worker trial II (VIEW II)
-
批准号:9788451
-
项目类别:
-
资助金额:$44.49万
-
财政年份:2018
-
负责人:Jeremy David Keenan
-
依托单位:
Village-Integrated Eye Worker trial II (VIEW II)
-
批准号:10200055
-
项目类别:
-
资助金额:$42.21万
-
财政年份:2018
-
负责人:Jeremy David Keenan
-
依托单位:
Admin Supplement: Village-Integrated Eye Worker Trial II (VIEW II)
-
批准号:10836220
-
项目类别:
-
资助金额:$8.65万
-
财政年份:2018
-
负责人:Jeremy David Keenan
-
依托单位:
Diversity Supplement: Village Integrated Eye Worker Trial II Validation Study
-
批准号:10361062
-
项目类别:
-
资助金额:$9.33万
-
财政年份:2018
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in Face-washing for Trachoma
-
批准号:8742315
-
项目类别:
-
资助金额:$66.39万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)
-
批准号:10247679
-
项目类别:
-
资助金额:$74.74万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in Face-washing for Trachoma
-
批准号:9336906
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)
-
批准号:10469420
-
项目类别:
-
资助金额:$79.76万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in Face-washing for Trachoma
-
批准号:8928185
-
项目类别:
-
资助金额:$46.97万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in Face-washing for Trachoma
-
批准号:9136819
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)
-
批准号:10688282
-
项目类别:
-
资助金额:$97.49万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)
-
批准号:10019541
-
项目类别:
-
资助金额:$74.95万
-
财政年份:2014
-
负责人:Jeremy David Keenan
-
依托单位:
Planning Grant for Parasitic Ulcer Treatment Trial
-
批准号:8281382
-
项目类别:
-
资助金额:$21.87万
-
财政年份:2012
-
负责人:Jeremy David Keenan
-
依托单位:
Optimal trachoma control after mass antibiotic distributions
-
批准号:7898753
-
项目类别:
-
资助金额:$20.67万
-
财政年份:2008
-
负责人:Jeremy David Keenan
-
依托单位:
Optimal trachoma control after mass antibiotic distributions
-
批准号:8120530
-
项目类别:
-
资助金额:$20.67万
-
财政年份:2008
-
负责人:Jeremy David Keenan
-
依托单位:
海外基金